Literature DB >> 15273148

Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.

Mihaela Peric1, Michael R Jacobs, Peter C Appelbaum.   

Abstract

Agar dilution MIC methodology was used to compare the activity of WCK 771 with those of ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin, piperacillin, piperacillin-tazobactam, imipenem, clindamycin, and metronidazole against 350 anaerobes. Overall, the MICs (in micrograms per milliliter) at which 50 and 90%, respectively, of the isolates tested were inhibited were as follows: WCK 771, 0.5 and 2.0; ciprofloxacin, 2.0 and 32.0; levofloxacin, 1.0 and 8.0; gatifloxacin, 0.5 and 4.0; moxifloxacin, 0.5 and 4.0; piperacillin, 2.0 and 64.0; piperacillin-tazobactam, < or =0.125 and 8.0; imipenem, 0.125 and 1.0; clindamycin, 0.125 and 16.0; and metronidazole, 1.0 and >16.0.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15273148      PMCID： PMC478502          DOI： 10.1128/AAC.48.8.3188-3192.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.

Authors:  R Bachoual; L Dubreuil; C J Soussy; J Tankovic
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.

Authors:  H Oh; N El Amin; T Davies; P C Appelbaum; C Edlund
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

Authors:  A Bauernfeind
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

7.  Characterization of a beta-lactamase from Clostridium clostridioforme.

Authors:  P C Appelbaum; S K Spangler; G A Pankuch; A Philippon; M R Jacobs; R Shiman; E J Goldstein; D M Citron
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

8.  Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.

Authors:  A Bauernfeind
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790
View more
  7 in total

Review 1.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

2.  Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study.

Authors:  Kapil D Mehta; Jai B Sharma; Ashok Anand; Pavan K Reddy N; Pramod Kadam; Khokan Debnath; Sandeep Bhapkar; Bini M Thampi
Journal:  Cureus       Date:  2022-04-20

Review 3.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model.

Authors:  Anasuya Patel; Ganesh V Sangle; Jinal Trivedi; Sushant A Shengule; Deepak Thorve; Mohan Patil; Nitin J Deshmukh; Bhushan Choudhari; Avinash Karade; Sangita Gupta; Sachin Bhagwat; Mahesh Patel
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 5.  Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.

Authors:  Sachin S Bhagwat; Manohar Nandanwar; Atul Kansagara; Anusuya Patel; Swapna Takalkar; Rajesh Chavan; Hariharan Periasamy; Ravindra Yeole; Prasad K Deshpande; Satish Bhavsar; Ashima Bhatia; Jaishid Ahdal; Rishi Jain; Mahesh Patel
Journal:  Drug Des Devel Ther       Date:  2019-12-24       Impact factor: 4.162

6.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

Review 7.  Pipeline of Known Chemical Classes of Antibiotics.

Authors:  Cristina d'Urso de Souza Mendes; Adelaide Maria de Souza Antunes
Journal:  Antibiotics (Basel)       Date:  2013-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.